^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    boditrectinib (AUM-601)

    i
    Other names: AUM-601, HL5101, NOV 1601, HL 5101, NOV1601, CHC2014, AUM601, AUM 601, CHC-2014, CHC 2014, HL-5101, NOV-1601
    Associations

    News

    Trials
    Company:
    AUM Biosci, CMG Pharma, Handok
    Drug class:
    pan-TRK inhibitor
    Related drugs:
    Associations

    News

    Trials
    over4years
    [VIRTUAL] A first-in-human study of NOV1601 (CHC2014), small-molecule inhibitor of TRK family proteins, in adult patients with solid organ malignancies (ESMO 2020)
    & National OncoVenture. Clinical trial identification: NCT04014257.
    Clinical • P1 data
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    boditrectinib (AUM-601)